Case Studies in Endocrinology J. Carl Pallais, M.D., M.P.H.

Associate Director, Residency Training Program Senior Physician, Division of Endocrinology

Brigham & Women’s Hospital

January 30, 2020

Disclosures

• None

3 Cases

• Hyperparathyroidism • Hyperprolactinemia • Male Hypogonadism

Case #1

67 yo woman with a history of HTN and hypothyroidism found to have a calcium of 11.1 mg/dL (nl < 10.5) on routine labs prior to a screening colonoscopy

Approach to hypercalcemia in the office

setting

Calcium Regulation

• Primary regulator of Ca is PTH

• PTH increases serum Ca Bone –↑mobilization of Ca Kidney –↑ calcium reabsorption –↑ 1 alpha hydroxylase GI –↑ dietary Ca absorption

• PTH decreases serum phos Baia.Nature Rev Nephrol.2015.

Circulating Calcium Concentration

• Only ~50% of circulating calcium is ionized – 10% bound to inorganic anions (phos, etc.) – 40% bound to Albumin

• Percentage bound is determined by pH

– Acidosis- ↓ bound , ↑ free – Alkalosis- ↑ bound, ↓ free

Costanzo.Physiology.2010..

[Ca]corrected = [Ca] measured + 0.8(4 - [Alb])

Causes of Hypercalcemia • #1= PTH-dependent

• #2= Malignancy • Others

– Milk-Alkali – Vitamin D excess

• Sarcoid, granulomatous disorders • Excess intake

– Increased bone turnover • Hyperthyroidism, Pagets, immobilization, vitamin A

PTH – Dependent Hypercalcemia • Adenoma (85%) • Hyperplasia (15%)

– Spontaneous – MEN I & IIA, Jaw Tumors Syndrome – Tertiary hyperparathyroidism

• Rare • Carcinoma • Ectopic PTH

– Lung, Ovarian, Thymus CA, PNET, Islets Tumor • FHH/NSHP/AHH

– Abnormal Ca-sensing receptor • Meds- Lithium

Normocalcemic Primary Hyperparathyroidism

Initial Evaluation

• Calcium, albumin (+/- ionized Ca) • Phosphate • PTH

If PTH suppressed: • 25-OH vit D;1,25 (OH)2 vit D; PTHrP;

TSH; ACE; Alk phos +/- bone scan • Imaging studies-CA, granulomatous dz

Case #1 Labs • Repeat calcium 10.9 mg/dl (nl <10.5)

• Albumin 3.6 g/dl • Phosphate 2.2 mg/dl (nl >2.5)

• PTH 105 pg/ml (nl <60)

Diagnosis = 1◦ Hyperparathyrodism

Epidemiology of 1⁰ Hyperparathyroidism

• Prevalence – Increased 6 fold since 1970s – Women > Men

• 233 vs 85 per 100K • ~1/50 postmenopausal F

• Incidence – ~100K new dx/yr – Increased with age

• Age ↑ gender difference

Yeh.JCEM.2013, Insogna.NEJM.2018

Women

Men

Women Men

Inci

denc

e p

er 1

00K

Age

Hyperparathyroidism: Symptoms (Then & Now)

• Bones – Osteitis fibrosa cystica, pseudogout, fractures→

osteopenia/osteoporosis • Stones

– Staghorn kidney, stones, DI → stones • Groans

– Pancreatitis, PUD → constipation, Abd pain • Psychiatric Overtones

– Stupor, delirium → fatigue, depressed mood

Asymptomatic incidental finding

Additional Work-Up

• 25-OH vitamin D Serum

• Creatinine & eGFR • 24h urine calcium and creatinine*

• R/O hypocalciuria & R/In hypercalciuria • Stone risk profile*

• Abdominal imaging (U/S, X-ray, CT)*

Renal

• Bone density & vertebral spine frx* • DXA (spine, hip, & distal 1/3 radius) • DXA-VFA or Dedicated spine imaging

Skeletal

*= New since 2008 guidelines

Pallais. NEJM.2004; Bilezikian.JBoneMinerRes.2002, JCEM 2009,*JCEM 2014.

Indications for Surgery

• Ca > 1.0 mg/dl above ULN Serum

• Crt clearance < 60 ml/min ? ‡ • Presence or ↑ risk of kidney stones*

• 24h UCa>400 mg or stones on imaging Renal

• Bone density & vertebral spine frx↓* • DXA T<-2.5 (spine, hip, & distal 1/3 radius) • Frx on DXA-VFA or vertebral imaging

Skeletal

Pallais. NEJM.2004; Bilezikian.JBoneMinerRes.2002, JCEM 2009,*JCEM 2014.

• < 50 yo Age

– Symptoms – Vitamin D deficiency ‾ Patient preference, poor follow-up

Relative Indications

*= New since 2008 guidelines

Parathyroidectomy • Localization

• U/S • Sestamibi Scan • 4D-CT • Good Surgeon !!!!

• Surgical techniques • Neck exploration • Minimally invasive

• Complications • Hypocalcemia • Hungry bone

Case #1 Work-Up • 67 yo, no h/o fractures or kidney stones • Labs:

– Calcium 10.9 mg/dl, (PTH 105 pg/mL) – 25-OH vitD – 38 ng/mL (nl>32)

– (Creatinine clearance > 60 ml/min) • 24h Urine calcium – 220 mg Ca • Abd U/S- no kidney stones • DEXA

– T:- 2.0 spine, -2.4 fem neck, -2.7 in hip, -2.8 wrist – VFA: no vertebral frx

Osteoporosis as indication for surgery

Case #1 Imaging/ Parathyroidectomy

• Tech-99 Sestamibi SPECT suspicious for a L lower parathyroid adenoma

• Neck ultrasound confirmed

• Resection of enlarged gland – intraop PTH 112 → 45 pg/ml

• Path- 900 mg gland w little stromal fat c/w adenoma

Improvement in BMD Post-surgical improvement • Spine

– 9% after 1 yr – 12% after 10 yr

• Femoral Neck – 5% after 1 yr – 10% after 10 yr

• Radius – 3% after 1 yr – 7% after 10 yr

Silverberg.NEJM.1999 & JCEM.2009; Rubin.JCEM.2008.

What If…

…BMD had been normal • If no indications for surgery, monitor:

– Serum calcium annually – Serum creatinine annually – BMD every 1-2 yrs* – Vertebral fracture assessment if clinical signs* – Renal stone assessment if clinical signs*

Bilezekian. JCEM.2014*, Khan.JCEM.2009

• Biochemical levels did not change significantly in > 10 yr of f/u

• However, accelerated bone loss may occur

What If… …Patient refused surgery • Available medical therapy include:

Case #2

32yo G2P2 woman with history of anxiety found to have a prolactin level of 56 ng/ml (nl <20) during evaluation of persistent amenorrhea 6 months after she stopped nursing her youngest child.

Approach to the patient with hyperprolactinemia

Prolactin Physiology Prolactin secretion from pituitary lactotrophs under tonic inhibitory hypothalamic control

• INHIBITORY SIGNALS –Dopamine

• STIMULATORY SIGNALS

TRH VIP Serotonin GnRH Histamine Angiotensin II Estrogen Oxytocin Breast/chest wall stimulation (spinal afferent) Stress, food-insulin, exercise, intercourse, sleep

• Prolactin is released in a pulsatile fashion 4-9 pulses/day w levels rising during late sleep

–Levels < 25 ng/ml in women (<20 ng/ml in men)

• Primary function is the regulation of lactation –Prolactin increases in pregnancy (200’s ng/ml) –Lactation when estrogen levels fall

• PRL inhibits LH & FSH secretion

Vance.NEJM.1994; Molitch.EndoMetabClinNorthAm.1992.

Prolactin

DDX of Hyperprolactinemia

• Pregnancy • Hypothyroidism

• Drug-Induced • CNS abnormalities • Prolactinoma

• Other

– Breast stimulation, chest wall lesions (zoster, etc.), seizure – Renal failure, liver dz

Drug-Induced

Molitch.Pituitary.2008, Peuskens.CNS Drugs.2014.

Aripiprazole -Partial D2 agonist, may be least

a/w ↑ prolactin levels

CNS Disorders

Molitch.Endocrinol Metab Clin North Am.1992.

Pituitary Disorders • Stalk disorders

– Trauma – Tumors – Infiltration – Arterial aneurysm

• Pituitary Macroadenomas – Stalk compression

Prol

actin

30

ng/m

l

Hypothalmic Disorders • Tumors

– Craniopharyngiomas – Meningiomas – Dysgerminomas – Gliomas – Lymphom – Metastatic disease

• Infiltrative dz/infection – Sarcoid – Tuberculosis – Eosinophilic granuloma

• Other – Irradiation, trauma

Prolactinoma • Benign pituitary adenomas

• Most common hormone secreting pituitary tumor – Account for ~40 % of pituitary tumors

• > 90% are small and slow growing

• Tumor size is correlated to prolactin levels – Macroadenoma (>1 cm) → PRL usually >200 ng/ml

• If prolactin < 100-150 ng/ml – Non-prolactin tumor w stalk compression – Hook effect- assay artifact at very high PRL concentration

– Idiopathic hyperprolactenemia (<2-3mm)

Molitch.1992.; Schlechte.NEJM.2003

Pituitary Anatomy • Anterior pituitary

– Lactotrophs- laterally • Vessels • Cavernous sinus • Cranial nerves • Chiasm • Sphenoid sinus

Lechan.EndoText.2004. Functional Anatomy of the Pituitary and Hypothalamus

Clinical Presentation Women • Amenorrhea/

oligomenorrhea • Infertility • Galactorrhea

– Up to 80%, not all symptomatic

• Tumor effects – Rare in women as most

tumors are small • Osteopenia

Schlechte.NEJM.2003; Trouillas.Neuroendocrinology.2019

Men • Tumor effects

– HA – CN palsy – Visual field defects – Hypopituitarism

• Hypogonadism – Decreased libido – Erectile dysfunction – Infertility

• Osteopenia • NOT galactorrhea

– Exceedingly rare

Initial Evaluation

• History and physical – Meds – Evidence of secondary causes – Mass effect

• Labs – Repeat prolactin (+/- serial dilutions) – hCG, TFTs, BUN/Crt, LFTs – +/- other pituitary function tests

• IGF-1, LH, FSH, gonadal steroids, cortisol • Imaging studies

– MRI with gadolinium better than I+ CT • If macroadenoma → formal visual field testing

Case # 2 • No physiologic or known secondary causes, no other

symptoms besides amenorrhea • Exam unremarkable except for expressive galactorrhea • Laboratory Tests

– Repeat PRL 70 ng/ml – hCG negative – BUN/Crt, LFT’s, TSH, FT4, IGF-1 all WNL – LH, FSH, and estrogen suppressed

• MRI showed a 5 mm pituitary adenoma not impinging on chiasm

• Not interested in further fertility

Indications for Treatment

• Macroadenoma or tumor growth • Hypogonadism • Infertility • Symptoms

– Galactorrhea – Hirsutism

Conservative monitoring is an option for pts

not interested in fertility & no other indication Klibansky.NEJM.2010, Melmed. JCEM.2011

Treatment Options • Dopamine agonists

– Bromocriptine – Cabergoline

• OCP – If small microadenoma in pt not desiring further fertility and

whose only indication for trx is amenorrhea • Surgery

– Unable to tolerate medical tx, unresponsive to tx (persistent chiasmal compression, ↑ tumor size), apoplexy

– High recurrence rate • XRT

– More definitive but higher risk of panhypopituitarism

Melmed. JCEM.2011

Bromocriptine vs Cabergoline • Cabergoline is easier to administer

– Cabergoline has a longer half life (can be dosed weekly) – Bromocriptine has more side effects

• Nausea, vomiting (50%) Nasal Congestion • HA (20%) Constipation • Orthostasis (20%) Fatigue, anxiety

• Cabergoline more effective

– PRL normalization (80% vs 60%) – Pts achieving >50% tumor shrinkage (96% vs 64%) – Persistently normal PRL after trx d/c’ed (60% vs 33%) – Cabergoline effective for tx of bromocriptine resistant tumors

• Bromocriptine may be preferred when fertility is an issue

– More experience w bromocriptine in pregnancy

Gillam.2006; Webster.NEJM.1994; Schlechte.NEJM.2003; Melmed.JCEM.2011; Huang.EndoMetClinNA.2019

Case # 2 • Treatment

– Dopamine agonist [or OCP] • Follow-up

– Prolactin- yearly – MRI

• If clinical evidence of tumor expansion • If considering trial off dopamine agonists

– After > 2yrs of uninterrupted treatment – Persistently normal prolactin measures

Cabergoline Withdrawal If initial adenoma < 2cm AND PRL has normalized, tumor shrank by

>50%, & no evidence of cavernous sinus invasion, can attempt to d/c cabergoline after 2 yrs of trx

Colao.NEJM.2003 & Clin Endo.2007, Melmed.JCEM.2011.

• Long-term remission possible

based on tumor size Before TX: – Non-tumoral ~ 75% – Microprolactinoma ~ 66% – Macroprolactinoma ~ 50% After TX: – No remnant tumor ~80% – Remnant tumor ~50%

• Renewed tumor growth was not seen 5 yrs after cabergoline w/d

Additional Consideration NEJM - January 4, 2007

• Long-term use of cabergoline for ↑ prolactin a/w TR but of unclear clinical significance – Mod TR in cabergoline vs controls: 54% vs 18%

Colao.JCEM.2008; Kars.JCEM.2008; Melmed.JCEM.2011; Vroonen.Neuroendocrinology.2019

• Use lowest dose of cabergoline to normalize prolactin & consider withdrawal trial depending on response

Case #3

58 yo man with a history of DM, HTN, and dyslipidemia was found to have an afternoon testosterone level of 185 ng/dl (nl

>270) after complaining of erectile dysfunction, diminished libido, and decreased energy.

Approach to the patient with androgen deficiency

“Andropause”

• Testosterone levels ↓ at a fairly constant rate – average ↓ 3.2 ng/dl / year Baltimore Longitudinal Study of Aging

• Increased frequency of testosterone values in the hypogonadal range with aging

Harman.JCEM.2001, Feldman.JCEM.2002, Morley.Metabolism.1997

Several cross-sectional and longitudinal studies have demonstrated a decline in serum testosterone with age

Hypogonadism in Aging Men

Harman. 2001

Who Has Androgen Deficiency?

Endocrine Society Clinical Practice Guideline:

We recommend diagnosing hypogonadism in men with symptoms and signs of testosterone

deficiency AND

unequivocally and consistently low serum testosterone levels

Bhasin.JCEM.2018.

Challenges We recommend diagnosing hypogonadism in men with symptoms and signs of testosterone deficiency AND

unequivocally low serum testosterone levels • Signs and symptoms are non-specific

– Common with age – Often seen in patients with normal testosterone levels

• Many barriers in determining what constitutes

“unequivocally low” testosterone levels

Androgen Deficiency Clinical findings depend on age of onset

– Fetal- hypospadias, microphallus, cryptorchidism – Prepubertal-incomplete sexual maturation – Adulthood- regression of sexual function, infertility, hot flashes

Most signs and symptoms in adult onset are non-specific

Pallais. 2007, *Wu.2010, Bhasin.2018.

More reliable features – Abnormal sexual development

• Prepubertal testes • High pitched voice • Eunuchoid proportions

– ↓ virilization – Azoospermia – New gynecomastia – Hot flashes – Fragility fracture

Less reliable features – Mild anemia – Decreased energy – Decreased aggressiveness – Depressed mood – Decreased muscle/strength – Impaired memory – Increased adiposity

Impaired sexual function*, ↓ libido*, ↓ spontaneous erections*

Signs and Symptoms of Sexual Dysfunction are Common

• High prevalence of sexual problems even in young men( <60 yo)

– By age 40, 40% of men reported some level of impaired sexual function

Wu. NEJM.2010; Laumann. JAMA.1999

• There is a waning in sexual function and libido with each decade

Massachusetts Male Aging Study (Feldman.1994, Araujo.2004)

• Decline in sexual function is associated with co-morbid conditions

Health Professional Follow-up Study (Bacon.2003)

Challenges in Testosterone Measurements

• Physiologic variations – Pulsatile secretion – Circadian variation – Protein binding

• Technical challenges – Tissue conversion and intracellular receptors

• No established physiologic testosterone threshold to guide therapy or confirm the diagnosis of androgen deficiency

– Only population norms

• Effect of medicines and co-morbid conditions

Normal Physiology • Hypothalamic-Pituitary-Gonadal

(HPG) Axis – GnRH – LH, FSH – Testosterone, gametogenesis

• Pulsatile gonadotropin secretion – ~10-12 pulses/d – Significant fluctuations in testosterone levels

(can be >50%)

• Circadian variation – Morning > evening – ~20% of normal subjects with testosterone

levels occasionally dropping into the “hypogonadal” range in a 24h period

Spratt.AmJPhysiol.1988.

Pulsatile GnRH

Testosterone Spermatogenesis

Testosterone

LH

FSH LH

Circulating Testosterone • Protein binding

– “Bioavailable” testosterone is non-SHBG bound fraction • ~55% tightly bound to SHBG • ~45% weakly bound to Albumin • ~1-3% free

Klee.MayoClinProc.2000, Bhasin.JCEM.2018.

Conditions that ↑ SHBG Aging Hepatitis Hyperthyroidism HIV Estrogen Anticonvulsants GH deficiency

Conditions that ↓ SHBG Obesity Nephrotic syndrome Hypothyroidism Acromegaly Androgens Insulin Glucocorticoids Progestins Familial

• Several factors alter SHBG levels

Bioavailable

Testosterone Measurements • Reliable assays for free or bioavailable testosterone

are not widely available – Commonly available free testosterone measurements are

not very reliable – Can estimate bioavailable androgens from total testosterone

and SHBG concentration

• Normative ranges in healthy young men vary among laboratories & assays

30% of pts in the mildly hypogonadal range have normal levels on repeat measurement

Bhasin.JCEM.2006, Rosner.JCEM.2007, Antonio.JCEM.2016, Bhasin.JCEM.2018.

Additional Limitations • Testosterone is a pro-hormone

– Enzymatic conversion in tissue • Dihydrotestosterone (5α Reductase) • Estrogen (Aromatase) • Inactivated (3α Reductase)

• Affect is mediated through

intracellular receptor

• No clear physiologic threshold for hypogonadism has been established

Feldman.Nature Reviews Cancer.2001, Winters.NIDA.1990.

Hypogonadism in Men (HIM), Hypogonadism with Estrogen Removal(HER)

• Chemical castration with different doses of testosterone add-back (HIM)

– 0, 1.25, 2.5, 5, or 10 g of testosterone gel • + Aromatase inhibitor (HER)

– Evaluate dose-response of various outcomes

Finkelstein, Lee, Burnett-Bowie, Pallais, et al NEJM.2013.

Physiologic Outcomes

Testosterone’s effect on many physiologic outcomes were dependent on estradiol levels • Pure androgenic effects

• PSA, Hct, lean mass, strength

• Strong estrogen effect • ↑ sexual fnx • ↓ body fat • ↓ bone turnover

Different outcomes had different testosterone “thresholds”

P=0.045 for HIM vs HER interaction

Finkelstein, Pallais, et al.NEJM.2013 & unpublished data.

Evaluation • Morning testosterone & SHBG measurement

–Confirm by repeating on more than one occasion

• LH & FSH to differentiate between primary and secondary causes

–Primary- high LH & FSH –Secondary- inappropriately low LH & FSH (may

within the “normal” range)

Primary Hypogonadism • Testicular defect • High LH, FSH, low testosterone • Causes

• Viral orchitis • Toxins

• Radiation, chemotherapy • Drugs

• Alcohol, ketoconazole, spironolactone, metronidazole, etomidate

• Trauma • Systemic diseases

• Cirrhosis, renal failure, granulomatous dz, HIV • Klinefelter Syndrome (47, XXY)

FSH LH

Secondary Hypogonadism (Hypogonadotropic Hypogonadism)

• Central defect • Inappropriately low LH, FSH, low testosterone • Causes

– Hypothalamic or pituitary disorders • Tumors, infiltrative diseases, head trauma • Hyperprolactinemia • Hemochromatosis

– Functional • Acute illness, eating disorders, depression, excessive

exercise, AIDS – Drugs

• Glucocorticoids, opiates, MJ, digitalis, exogenous estrogens

– Idiopathic • Anosmic vs normosmic

FSH LH

Primary vs Secondary • Further evaluation

– Primary • Karyotype- including test for mosaic 46,XY/47,XXY

– Secondary • Prolactin • Iron studies • Pituitary function testing • MRI • ACE-levels • Genetic testing / counseling for IHH

– Consider BMD for any cause of hypogonadism • Implications for fertility

– Better success achieving fertility in secondary hypogonadism

Pallais.Hypogonadotropic Hypogonadism Overview. 2007; Bhasin.JCEM.2018.

Evaluation of Hypogonadism

Bhasin.JCEM.2018

Fasting am T/SHBG (FT)

X 2

+ Sx

Dx: Hypogonadism

LH / FSH

Primary Hypogonadism Secondary Hypogonadism

*Consider reversible functional causes

Bhasin.JCEM.2018.

History and physical examination Ascertain symptoms and signs of testosterones (T) deficiency

Evaluate for systematic illness, drugs, nutritional deficiency that could lower T

Measure morning fasting total T* (and free T* if altered SHBG or borderline total T, Table 2$)

Sermon analysis if fertility issue

Confirm by repeating morning fasting total T (and free T$)

Diagnosis of hypogonadism is confirmed Consider other causes of

symptoms and signs

Consider potentially reversible functional causes, Table 1•

Measure prolactin, iron saturation Evaluate other

pituitary hormones (if clinically indicated%)

Pituitary MRI (if indicated^)

Obtain karyotype to diagnose Klinefelter

syndrome (if clinical indication)

Measure LH and FSH

Functional Hypogonadism • Caused by conditions that suppress testosterone

concentrations but are potentially reversible with treatment of the underlying etiology

• Hyperprolactinemia • Opioids, anabolic steroids, glucocorticoids • ETOH, MJ use* • Systemic illness* • Nutritional deficiencies/excessive exercise • Severe obesity, some sleep disorders • Organ failure (liver, heart, lung, renal)* • Comorbid illness a/w aging*

Bhasin.JCEM.2018.

* Combined 1⁰ & 2⁰

hypogonadism

Who to treat?

Endocrine Society Clinical Practice Guideline “We recommend testosterone therapy in hypogonadal men

to induce and maintain secondary sex characteristics and correct symptoms of testosterone deficiency”

Bhasin.JCEM.2018.

Indications for Treatment • Established

– Micropenis – Delayed puberty – Classic hypogonadism

• Prepubertal onset • Klinefelter • Trauma/torsion/tumor • Pituitary/CNS injury

FDA approved for these indications

• Controversial – Aging – Hypogonadism of chronic disease

Limited efficacy & safety data

Don’t Treat Men with NORMAL levels!!

Contraindications for Treatment • Contraindications

• Prostate cancer • Breast cancer

• Relative contraindications • Desire for fertility in near term • Prostate nodule or induration • PSA >4 ng/mL (or >3 if high risk) • Severe BPH • Erythrocytosis (Hct > 48%) • Untreated obstructive sleep apnea • Unstable CHF • MI or CVA in last 6 mo • Thrombophilia

Bhasin.JCEM.2018

Benefits & Side Effects • Benefits

– Improved anemia – Improved bone density (no fracture data) – Improved sexual function (marginally) – Improved body composition (but not vitality or physical function)

• Side effects

Spitzer. Nature Reviews.2013; *Basaria.NEJM.2010; *Vigen.JAMA.2013; Bhasin.JCEM.2018.

T Trials: Effects of Testosterone Treatment

on Older Men • 790 men (12 centers)

– ≥ 65 yo – T < 275 ng/dL – + Hypogonadal sx’s

• Sexual dysfunction • Difficult walking • Low vitality

• Randomized (1yr) – T gel – Placebo

• Exclusion: – Prostate CA or high risk

of prostate CA – IPSS >19 – Other causes of ↓T – MI/CVA w/i 3mo,

unstable angina/CHF, or BP >160/100

– Severe depression

Snyder.NEJM.2016, Resnick.JAMA.2017, Budoff.JAMA.2017, Roy.JAMA IM.2017, Snyder.JAMA IM.2017.

T Trials Parameter N= 1⁰ outcome Results

Anemia 126 ↑Hb by 1g/dL 54% vs 15%

Bone density 211 Quantitative CT (vBMD & finite element analysis)

↑vBMD & estimated strength of spine & hip

Sexual function 450 Psychosexual daily questionnaire (0-12)

Baseline 1.5; Tx difference 0.6

Physical function 387 6’ walk test Not significant

Vitality 474 Functional Assessment Questionnaire

No change

Cognitive Function 493 Delayed paragraph recall (0-50) & others

No change

Coronary artery plaque volume

170 Plaque volume by CCTA ↑ plaque volume (40 vs 4 mm3)

No frx data

↓Effect after 6mo

No MI data

Roy.JAMA IM.2017; Snyder.JAMA IM.2017; Snyder.NEJM.2016, Resnick.JAMA.2017, Budoff.JAMA.2017.

Not

Si

gnifi

cant

Treatment Efficacy: Sexual Function

• Limited benefit – Small improvement in sexual

activity index • +0.6 vs placebo (out of 12)

• Statistically significant • Uncertain if clinically significant

– Effect waned after 6 months – PDE5 inhibitor had greater effect

• IEFF (0-30): Testosterone vs sildenafil • +2.64 vs +5.7

Snyder.NEJM.2016

Limited generalizability Healthy bias (80% excluded) Avg age 72, 90% white

Chan

ge in

Sex

ual A

ctiv

ity S

core

Benefits & Side Effects • Benefits

– Improved anemia – Improved bone density (no fracture data) – Improved sexual function (marginally) – Improved body composition (but not vitality or physical function)

• Side effects – Adverse prostate effects

• Worsening BPH and prostate cancer – Cardiovascular events?* – Reduced sperm production and fertility – Induction or worsening of obstructive sleep apnea – Erythrocytosis – Gynecomastia – Acne and oily skin – Male pattern balding

Spitzer. Nature Reviews.2013; *Basaria.NEJM.2010; *Vigen.JAMA.2013; Bhasin.JCEM.2018.

Effects on the Prostate • Moderate increase in prostate volume

• Increase in PSA within the normal range (0.2-0.5 ng/ml)

– T Trials: 6% of men on T ≥ 1ng/ml vs 2% placebo

• Reviews of variable quality trials (3mo - 3yr) have shown conflicting results in the rate of all combined prostate events in testosterone treated group c/t placebo

– prostate CA, biopsy, PSA>4 ng/ml, ↑IPSS>4

• Insufficient years of follow-up to determine clear effect on prostate cancer

Calof.J Gerontology.2005, Bhasin.JCEM.2010, Fernandez-Balsells.JCEM.2010, Snyder.NEJM.2016.

Effects on the Prostate

Fernandez-Balsells.JCEM.2010.

Calof. J Gerontoloy.2005

RR (CI) T tx Controls

Biopsy

Cancer

Composite prostate outcomes higher in T

group vs controls

OR 1.8 (p<0.05)

Cardiovascular Effects • Testosterone treatment increased the rate of CV events in

men with multiple risk factors

*Vigen.JAMA.2013.

RCT in frail men (avg age 74 yo) Observational study s/p cardiac cath

Dea

th, M

I, or

CVA

OR 5.8 (2.0-16.8)

OR 5.8 (p<0.001) HR 1.29 (p=0.02)

*Basaria.NEJM.2010.

• Drug Safety Communication about possible CV risks (1/2014) – “(FDA) is investigating the risk of stroke, heart attack, and death in men

taking FDA-approved testosterone products.”

• Label Warning about potential venous blood clots (6/2014) – “(FDA) is requiring manufacturers to include a general warning in the drug

labeling of all approved testosterone products about the risk of blood clots in the veins.”

• Caution about treatment of low levels & symptoms due to aging (3/2015) – “(FDA) cautions that prescription testosterone products are approved only for

men who have low testosterone levels caused by certain medical conditions.” • The benefit & safety of these medications have not been established for the treatment of

low testosterone levels due to aging, even if symptoms seem related to low testosterone.

• Inform of possible increased risk of heart attack and stroke (3/2015) • Label change to reflect possible increased risk of heart attacks and strokes a/w testosterone

Treatment

•The risk/benefit ratio for testosterone replacement in older men is more difficult to determine than in younger men

•No mortality data available for the long term use of testosterone replacement

Testosterone Formulations • Intramuscular

– Testosterone enanthate/cypionate- 100 mg/wk or 200 mg /2 wks • Supraphysiologic peak and hypogonadal trough levels

– Testosterone undecanoate- 750 mg q 10 wks • Concern for pulmonary oil microembolism and anaphylaxis

• Transdermal – Patch (2-4 mg)- 1 or 2 patches/night

• Skin irritation – 1% /1.62%/2% Gel – ~30-100 mg/d to extremities/trunk/axilla

• Potential transfer to female partner or child by direct contact • Moderately high DHT levels (lowers T:DHT ratio)

• Buccal bioadhesive tablets / Nasal Spray/ Oral (new) – 30 mg bioadhesive tablets bid / 5.5 mg – 2 pumps tid/ 237 mg bid

• Mucosal irritation, altered taste • Testosterone pellets

– 75 mg pellets- 2-6 pellets implanted sc q 3-6 months • Surgical insertion, may extrude spontaneously

Bhasin.JCEM.2018.

Goals and Follow-Up • Evaluate for response & side effects at 3-6 months and

then annually

• Measure testosterone levels 3-6 months after starting therapy & then yearly

– Aim for testosterone levels in the mid-nl range

• Check Hct at baseline, 3-6 months, & then yearly – Stop tx if Hct>54% until it drops to safe level & restart lower dose;

evaluate pt for hypoxia and sleep apnea

• Shared decision making about prostate monitoring (55-69 yo) – Digital rectal exam & PSA at baseline, at 3-12 months, and then in

accordance to guidelines – Refer if: 1) abnl exam, 2) ↑ PSA > 1.4 ng/ml within a yr, 3) PSA >4

ng/ml, 4) worsening BPH

Bhasin.JCEM.2018.

Case # 3 • History & Physical

– Pt recently started on narcotics for back injury – Reported increased stressors at work & home – ED was long-standing

• Had h/o peripheral vascular disease • On multiple antihypertensive agents

– Fatigue temporally correlated to his injury – Father and uncle with prostate cancer – Obese with BMI 34, no other signs of hypogonadism

• Lab tests normalized after narcotics d/c’ed – Repeat morning testosterone measurements

• T 300-400 ng/dl range with low SHBG levels – LH, FSH, & prolactin WNL

Case # 3 • Pt initially disappointed to have “low” T levels

• Discussed – Problems related to testosterone measurements (physiologic

variations, not a measure of physiologic activity, unclear what constitutes “normal” values)

– How testosterone levels tend to be lower in obesity (bec of ↓SHBG) – Effects of drugs & stress on the HPG axis – Likely multi-factorial cause of his ED – Potential risk factors with testosterone therapy

• Testosterone replacement not initiated and pt had a good response to tadalafil

Thank You!

Summary Key points: • Primary hyperparathyroidism is a common cause of hypercalcemia • Major causes of persistent hyperprolactinemia include drugs, prolactinomas,

and hypothalamic lesion • Testosterone measurements in men should be interpreted with caution

Next best steps: • Judicious interpretation of clinical context, laboratory measurements, and

imaging studies are necessary for the evaluation and treatment of hypercalcemia, hyperprolactinemia, and male hypogonadism